Company intelligence / Profile preview

GPBio

Tokyo-to, Japan

Ownership: Private
Development stage: Other

Overview

GP Biosciences has two primary programs in development: GB-102 (in preclinical stage for chronic kidney diseases) and RY106/RY107 (in discovery stage for genetic diseases)

Therapeutic areas: CardiovascularRare DiseasesInfectious Diseases
Modalities: Gene therapymRNA vaccine
Industry: Biotech

Partnerships

REYON PHARMACEUTICAL Co., Ltd. (collaboration on drug development)

Beyond the preview

Go deeper on GPBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GPBio.

Explore the full profile